Trials / Completed
CompletedNCT05878561
A Study to Evaluate the Efficacy and Safety of BR1015 Combination Therapy
A Randomized, Double-blind, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of BR1015 Combination Therapy in Comparison With Fimasartan Monotherapy for Essential Hypertension Patients Not Adequately Responded by Fimasartan 30 mg
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 248 (actual)
- Sponsor
- Boryung Pharmaceutical Co., Ltd · Industry
- Sex
- All
- Age
- 19 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this clinical trial is to evaluate the efficacy and safety of BR1015 Combination therapy group in comparison with Fimasartan monotherapy group at Week 8 for essential hypertension patients who do not adequately responded by Fimasartan 30 mg
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Fimasartan + Indapamide | a fixed dose combination |
| DRUG | Fimasartan + Indapamide placebo | a fixed dose combination |
Timeline
- Start date
- 2022-11-09
- Primary completion
- 2024-12-02
- Completion
- 2024-12-02
- First posted
- 2023-05-26
- Last updated
- 2024-12-20
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT05878561. Inclusion in this directory is not an endorsement.